Onco-Summaries: Daily Oncology Updates at a Glance
- Oncofocus Team
- Jul 21
- 1 min read
15/07/2026
Sacituzumab tirumotecan (sac-TMT) + pembrolizumab improved PFS vs chemo + pembrolizumab in PD-L1–negative NSCLC (Ref)
Sichuan Kelun-Biotech announced positive Phase 3 OptiTROP-Lung06 trial results for its TROP2 ADC sacituzumab tirumotecan (sac-TMT, SKB264/MK-2870)
Combination of sac-TMT + pembrolizumab (KEYTRUDA®) in PD-L1-negative, non-squamous NSCLC met its primary endpoint of progression-free survival (PFS) at interim analysis
It showed statistically significant and clinically meaningful improvement in PFS vs chemo + pembrolizumab
Positive trend in overall survival (OS) was observed; safety profile consistent with earlier studies
Regulatory Path: Company will communicate results to China’s Center for Drug Evaluation (CDE)
KEYTRUDA delivers first-ever PFS benefit over chemotherapy in frontline dMMR endometrial cancer (Ref)
Merck announced that its Phase 3 KEYNOTE-C93 trial met its primary progression-free survival (PFS) endpoint, showing KEYTRUDA (pembrolizumab) monotherapy significantly outperformed platinum doublet chemotherapy in previously untreated patients with dMMR advanced or recurrent endometrial cancer
An interim analysis by an independent Data Monitoring Committee also showed a trend toward improved overall survival (OS, the trial's other primary endpoint), though OS data are not yet mature
Clinically meaningful improvements were also seen in overall response rate (ORR), complete response rate (CRR), and duration of response (DOR)
Safety profile was consistent with prior studies; no new safety signals identified
Results will be presented at an upcoming medical meeting and shared with regulators
Comments